Bleeding rates for all patients by various risk group and treatment strategy
| Group | Heparin+compress n (%) | Heparin+device n (%) | *ARD (RRR)[NNT] | Bival+compress n (%) | Bival+device n (%) | †ARD (RRR) [NNT] |
|---|---|---|---|---|---|---|
| Overall | 612 (2.9) | 169 (2.6) | 0.3 (0.10) [333] | 253 (1.9) | 44 (1.0) | 0.8 (0.42) [125] |
| Male | 287 (2.0) | 70 (1.6) | 0.4 (0.20) [250] | 106 (1.2) | 24 (0.8) | 0.4 (0.33) [250] |
| Female | 325 (4.6) | 99 (4.5) | 0.1 (0.02) [1000] | 147 (3.2) | 20 (1.3) | 1.9 (0.59) [53] |
| 2B3A inhibitors | ||||||
| STEMI | 228 (8.1) | 53 (5.9) | 2.2 (0.27) [45] | 16 (7.5) | 7 (7.0) | 0.5 (0.07) [200] |
| NSTEMI | 160 (4.0) | 57 (3.7) | 0.3 (0.08) [333] | 17 (4.0) | 6 (3.4) | 0.6 (0.15) [167] |
| Stable Angina | 66 (2.4) | 13 (1.5) | 0.9 (0.37) [111] | 14 (3.6) | 2 (2.0) | 1.6 (0.44) [62] |
| No 2B3A inhibitors | ||||||
| STEMI | 40 (4.0) | 5 (2.5) | 1.5 (0.37) [66] | 23 (4.7) | 10 (4.0) | 0.7 (0.15) [143] |
| NSTEMI | 69 (1.2) | 29 (1.6) | 0.4 (0.33) [250] | 100 (1.9) | 14 (0.7) | 1.2 (0.63) [83] |
| Stable Angina | 49 (0.9) | 12 (1.0) | 0.1 (0.11) [1000] | 83 (1.3) | 5 (0.3) | 1.0 (0.76) [100] |
*Statistics for device effect among heparin patients.
†Statistics for device among bivalirudin patients.
ARD, absolute risk difference; bival, bivalirudin; compress, compression; NNT, number needed to treat; NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; RRR, relative risk reduction.